Who was studied?
Planned enrollment: 30 patients with recurrent or metastatic refractory NSCLC.
What does the publication report?
A single-center, single-arm phase II study is planned with ORR as its primary endpoint.
Safety findings
Adverse events will be assessed prospectively; observed safety results are not reported.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol) · DOI: 10.21037/tlcr-2026-1-0203 · PMID: 42291342
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.